易损冠状动脉粥样硬化斑块的经皮冠状动脉介入治疗
本研究在898例心肌梗死患者三支血管成像中,将182例造影非阻塞但IVUS斑块负荷≥65%的易损斑块随机分为BVS+GDMT或单用GDMT。25个月随访BVS组MLA显著大于GDMT组(6.9±2.6 vs 3.0±1.0 mm2,差异3.9 mm2,95%CI 3.3-4.5,p<0.0001),24个月TLF两组相似(4.3% vs 4.5%,p=0.96)。
要点
- 造影轻度但IVUS斑块负荷≥65%的易损斑块行BVS安全,随访MLA显著增大。
- BVS组与GDMT组24个月靶病变失败率相似(4.3% vs 4.5%)。
- 病变相关MACE BVS组4.3% vs GDMT组10.7%(OR 0.38,95%CI 0.11-1.28,p=0.12)。
核心结论
- 对造影轻度但斑块负荷大的易损斑块行PCI安全,显著增大随访MLA,并伴有利长期临床结局,值得开展充分把握度的随机试验。
研究设计与样本
- PROSPECT ABSORB随机对照试验,15个中心,182例心肌梗死后成功PCI所有限流病变且三支血管IVUS-NIRS成像患者随机(93例BVS+GDMT,89例单用GDMT)。
主要发现
- 随机病变造影直径狭窄中位数41.6%,斑块负荷中位数73.7%,MLA中位数2.9 mm2,最大脂质斑块含量中位数33.4%。
- 25个月造影随访完成167例(91.8%),临床随访中位4.1年。
- BVS组随访MLA 6.9±2.6 mm2 vs GDMT组3.0±1.0 mm2,最小二乘均值差3.9 mm2(95%CI 3.3-4.5,p<0.0001)。
- 24个月靶病变失败BVS组4.3% vs GDMT组4.5%(p=0.96)。
- 病变相关MACE BVS组4.3% vs GDMT组10.7%(OR 0.38,95%CI 0.11-1.28,p=0.12)。
关键数值与推荐
- 入选标准:心肌梗死后成功PCI所有限流病变,造影非阻塞狭窄不计划PCI但IVUS斑块负荷≥65%。
- 主要有效性终点:方案驱动的25个月随访IVUS衍生MLA。
- 主要安全性终点:24个月随机靶病变失败(心源性死亡、靶血管相关MI或临床驱动的靶病变血运重建)。
临床怎么用
- 对造影轻度但IVUS斑块负荷≥65%的易损斑块,可考虑BVS联合GDMT以增大管腔并可能改善长期结局。
- 需注意主要临床终点非把握度设计,结果应视为假设生成。
局限性
- 主要安全性和临床有效性终点非把握度设计。
- 造影随访完成率91.8%,非全部患者。
- 结论需充分把握度的随机试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute coronary syndromes most commonly arise from thrombosis of lipid-rich coronary atheromas that have large plaque burden despite angiographically appearing mild. OBJECTIVES: This study sought to examine the outcomes of percutaneous coronary intervention (PCI) of non-flow-limiting vulnerable plaques. METHODS: Three-vessel imaging was performed with a combination intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) catheter after successful PCI of all flow-limiting coronary lesions in 898 patients presenting with myocardial infarction (MI). Patients with an angiographically nonobstructive stenosis not intended for PCI but with IVUS plaque burden of ≥65% were randomized to treatment of the lesion with a bioresorbable vascular scaffold (BVS) plus guideline-directed medical therapy (GDMT) versus GDMT alone. The primary powered effectiveness endpoint was the IVUS-derived minimum lumen area (MLA) at protocol-driven 25-month follow-up. The primary (nonpowered) safety endpoint was randomized target lesion failure (cardiac death, target vessel-related MI, or clinically driven target lesion revascularization) at 24 months. The secondary (nonpowered) clinical effectiveness endpoint was randomized lesion-related major adverse cardiac events (cardiac death, MI, unstable angina, or progressive angina) at latest follow-up. RESULTS: A total of 182 patients were randomized (93 BVS, 89 GDMT alone) at 15 centers. The median angiographic diameter stenosis of the randomized lesions was 41.6%; by near-infrared spectroscopy-IVUS, the median plaque burden was 73.7%, the median MLA was 2.9 mm2, and the median maximum lipid plaque content was 33.4%. Angiographic follow-up at 25 months was completed in 167 patients (91.8%), and the median clinical follow-up was 4.1 years. The follow-up MLA in BVS-treated lesions was 6.9 ± 2.6 mm2 compared with 3.0 ± 1.0 mm2 in GDMT alone-treated lesions (least square means difference: 3.9 mm2; 95% confidence interval: 3.3 to 4.5; p < 0.0001). Target lesion failure at 24 months occurred in similar rates of BVS-treated and GDMT alone-treated patients (4.3% vs. 4.5%; p = 0.96). Randomized lesion-related major adverse cardiac events occurred in 4.3% of BVS-treated patients versus 10.7% of GDMT alone-treated patients (odds ratio: 0.38; 95% confidence interval: 0.11 to 1.28; p = 0.12). CONCLUSIONS: PCI of angiographically mild lesions with large plaque burden was safe, substantially enlarged the follow-up MLA, and was associated with favorable long-term clinical outcomes, warranting the performance of an adequately powered randomized trial. (PROSPECT ABSORB [Providing Regional Observations to Study Predictors of Events in the Coronary Tree II Combined with a Randomized, Controlled, Intervention Trial]; NCT02171065).
引用
- Stone GW, Maehara A, Ali ZA, et al. Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque. J Am Coll Cardiol. 2020. PMID: 33069847. doi:10.1016/j.jacc.2020.09.547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。